Cited by 2,409Glioma Diagnosis and TreatmentMedical Imaging Techniques and ApplicationsOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Response criteria for phase II studies of supratentorial malignant glioma.

Macdonald, D R, Cascino, T L, Schold, S C, Cairncross, J G·1990·Journal of Clinical Oncology

DOI 10.1200/jco.1990.8.7.1277

Open this paper in CoChat — free account

Abstract

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.

Integrity signals

Registry

Crossref · 10.1200/jco.1990.8.7.1277

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Successful chemotherapy for recurrent malignant oligodendroglioma
Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345
Self-citation
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors
Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178
Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.
Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151
Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas
Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149
Steroid‐induced CT changes in patients with recurrent malignant glioma
Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100
Self-citation
Computerized tomography in the prognosis of malignant cerebral gliomas
Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42
Criteria and definitions for response and relapse in children with brain tumors
Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour
Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33
Self-citation
The accuracy of volumetric measurement of high-grade gliomas
Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32

Show all 11 references

Sorted by citations

Items 601–700 of 1,001

Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria
Radbruch, A., Lutz, K., Wiestler, B., Baumer, P., Heiland, S., Wick, W., & Bendszus, M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor200 · Cited by 83
Salvage temozolomide for prior temozolomide responders
Franceschi, E., Omuro, A. M. P., Lassman, A. B., Demopoulos, A. M., Nolan, C. P., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21564 · Cited by 83
Addition of Bevacizumab to Standard Radiation Therapy and Daily Temozolomide Is Associated With Minimal Toxicity in Newly Diagnosed Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Kirkpatrick, J. P., Reardon, D. A., Peters, K. B., Herndon, J. E., Marcello, J. E., Bailey, L., Threatt, S., Sampson, J. H., et al. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.08.058 · Cited by 82
AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma
Brandes, A. A., Finocchiaro, G., Zagonel, V., Reni, M., Caserta, C., Fabi, A., Clavarezza, M., Maiello, E., Eoli, M., Lombardi, G., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now035 · Cited by 82
Diagnostic Accuracy of PET Tracers for the Differentiation of Tumor Progression from Treatment-Related Changes in High-Grade Glioma: A Systematic Review and Metaanalysis
de Zwart, P. L., van Dijken, B. R. J., Holtman, G. A., Stormezand, G. N., Dierckx, R. A. J. O., van Laar, P. J., & van der Hoorn, A. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233809 · Cited by 87
Amino Acid PET in Neurooncology
Galldiks, N., Lohmann, P., Fink, G. R., & Langen, K. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264859 · Cited by 82
Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status
Kurzwelly, D., Glas, M., Roth, P., Weimann, E., Lohner, H., Waha, A., Schabet, M., Reifenberger, G., Weller, M., & Herrlinger, U. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0032-0 · Cited by 82
Gliomatosis cerebri: Molecular pathology and clinical course
Herrlinger, U., Felsberg, J., Küker, W., Bornemann, A., Plaßwilm, L., Knobbe-Thomsen, C. B., Strik, H. M., Wick, W., Meyermann, R., DICHGANS, J., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10297 · Cited by 82
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma
Brandes, A. A. (2006) · Neuro-Oncology · doi:10.1215/15228517-2006-005 · Cited by 82
Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomas
Stragliotto, G., Vega, F., Stasiecki, P., Gropp, P., Poisson, M., & Delattre, J. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00592-7 · Cited by 82
Thalidomide as an Anti-angiogenic Agent in Relapsed Gliomas
Short, S. C., Traish, D., Dowe, A., Hines, F., Gore, M. E., & Brada, M. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1006414804835 · Cited by 81
Palliative Reirradiation for Progressive Diffuse Intrinsic Pontine Glioma
Fontanilla, H. P., Pinnix, C. C., Ketonen, L., Woo, S. Y., Vats, T. S., Rytting, M., Wolff, J. E. A., & Mahajan, A. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318201a2b7 · Cited by 81
Assessment of Brain Tumor Response: RANO and Its Offspring
Eisele, S. C., Wen, P. Y., & Lee, E. Q. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0413-5 · Cited by 81
Practical guidelines for the treatment of malignant gliomas.
Chamberlain, M. C., & Kormanik, P. A. (1998) · PubMed Central · Cited by 80
Temozolomide in Combination With Irinotecan for Treatment of Recurrent Malignant Glioma
Gruber, M. L., & Buster, W. P. (2004) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000045852.88461.80 · Cited by 80
Dynamic MRI Using Iron Oxide Nanoparticles to Assess Early Vascular Effects of Antiangiogenic versus Corticosteroid Treatment in a Glioma Model
Várallyay, C. G., Muldoon, L. L., Gahramanov, S., Wu, Y. J., Goodman, J. A., Li, X., Pike, M. M., & Neuwelt, E. A. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.162 · Cited by 80
Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study
Hattingen, E., Jurcoane, A., Bähr, O., Rieger, J., Magerkurth, J., Anti, S., Steinbach, J. P., & Pilatus, U. U. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor132 · Cited by 80
Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.
Bessell, E. M., Graus, F., Punt, J. A., Firth, J. L., Hope, D., Moloney, A. J., López‐Guillermo, A., & Villà, S. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.945 · Cited by 80
Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis
Hanna, C. R., Lawrie, T. A., Rogozińska, E., Kernohan, A., Jefferies, S., Bulbeck, H., Ali, U. M., Robinson, T., & Grant, R. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013261.pub2 · Cited by 79
Pharmacotherapy of Epileptic Seizures in Glioma Patients: Who, When, Why and How Long?
Wick, W., Menn, O., Meisner, C., Steinbach, J. P., Hermisson, M., Tatagiba, M. S., & Weller, M. (2005) · Oncology Research and Treatment · doi:10.1159/000086375 · Cited by 79
A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)
Hutterer, M., Nowosielski, M., Haybaeck, J., Embacher-Aichhorn, S., Stockhammer, F., Gotwald, T., Holzner, B., Capper, D., Preusser, M., Marosi, C., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not161 · Cited by 80
Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study
Boxerman, J. L., Zhang, Z., Safriel, Y. I., Larvie, M., Snyder, B. S., Jain, R., Chi, T. L., Sorensen, A. G., Gilbert, M. R., & Barboriak, D. P. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not049 · Cited by 79
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
Butowski, N. A., Lamborn, K. R., Lee, B. L., Prados, M. D., Cloughesy, T. F., DeAngelis, L. M., Abrey, L. E., Fink, K., Lieberman, F. S., Mehta, M. P., et al. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9705-3 · Cited by 79
Magnetic Resonance Imaging-Based Radiomic Profiles Predict Patient Prognosis in Newly Diagnosed Glioblastoma Before Therapy
McGarry, S. D., Hurrell, S. L., Kaczmarowski, A. L., Cochran, E. J., Connelly, J., Rand, S. D., Schmainda, K. M., & LaViolette, P. S. (2016) · Tomography · doi:10.18383/j.tom.2016.00250 · Cited by 79
Salvage Chemotherapy with CPT-11 for Recurrent Glioblastoma Multiforme
Chamberlain, M. C. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1014532202188 · Cited by 79
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma
Paleologos, N. A., Macdonald, D. R., Vick, N. A., & Cairncross, J. G. (1999) · Neurology · doi:10.1212/wnl.53.5.1141 · Cited by 79
Self-citation
High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques
Henriksen, O. M., Álvarez‐Torres, M. D. M., Figueiredo, P., Hangel, G. J., Keil, V. C., Nechifor, R. E., Riemer, F., Schmainda, K. M., Warnert, E. A. H., Wiegers, E. C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.810263 · Cited by 78
SEQUENTIAL SALVAGE CHEMOTHERAPY FOR RECURRENT INTRACRANIAL HEMANGIOPERICYTOMA
Chamberlain, M. C., & Glantz, M. (2008) · Neurosurgery · doi:10.1227/01.neu.0000325494.69836.51 · Cited by 78
Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
Tosoni, A., Franceschi, E., Ermani, M., Bertorelle, R., Bonaldi, L., Blatt, V., & Brandes, A. A. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9600-y · Cited by 78
Bevacizumab for recurrent ependymoma
Green, R. M., Cloughesy, T. F., Stupp, R., DeAngelis, L. M., Woyshner, E., Ney, D. E., & Lassman, A. B. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c1df34 · Cited by 78
Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles
Barbagallo, G. M. V., Paratore, S., Caltabiano, R., Palmucci, S., Parra, H. J. S., Privitera, G., Motta, F., Lanzafame, S., Scaglione, G., Longo, A., et al. (2014) · Neurosurgical FOCUS · doi:10.3171/2014.9.focus14502 · Cited by 79
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
Urgoiti, G. B. R., Singh, A. D., & Easaw, J. C. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0826-3 · Cited by 78
MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study
Vrabec, M., Cauter, S. V., Himmelreich, U., Gool, S. W. V., Sunaert, S. G., Vleeschouwer, S. D., Šuput, D., & Demaerel, P. (2010) · Neuroradiology · doi:10.1007/s00234-010-0802-6 · Cited by 78
Temozolomide
Darkes, M. J. M., Plosker, G. L., & Jarvis, B. (2002) · American Journal of Cancer · doi:10.2165/00024669-200201010-00006 · Cited by 78
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Uhm, J. H. (2010) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(10)79301-7 · Cited by 78
Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications
Li, Y., Saad, A., Clarke, J. L., & Cha, S. (2017) · Brain Tumor Research and Treatment · doi:10.14791/btrt.2017.5.1.1 · Cited by 78
Efficacy of gamma knife radiosurgery for nonfunctioning pituitary adenomas: a quantitative follow up with magnetic resonance imaging—based volumetric analysis
Wowra, B., & Stummer, W. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.97.supplement_5.0429 · Cited by 78
Defining a therapeutic window for the novel TGF ‐β inhibitor LY 2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model
Gueorguieva, I., Cleverly, A., Stauber, A. J., Pillay, N. S., Rodon, J. A., Miles, C., Yingling, J. M., & Lahn, M. M. F. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12256 · Cited by 78
EORTC study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
Brandes, A. A., Stupp, R., Hau, P., Lacombe, D., Gorlia, T., Tosoni, A., Mirimanoff, R. O., Kros, J. M., & van den Bent, M. J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.10.029 · Cited by 77
Advanced MRI in the management of adult gliomas
Jenkinson, M. D., du Plessis, D. G., Walker, C. A., & Smith, T. S. (2007) · British Journal of Neurosurgery · doi:10.1080/02688690701642020 · Cited by 77
Osmotic blood–brain barrier disruption chemotherapy for diffuse pontine gliomas
Hall, W. A., Doolittle, N. D., Daman, M., Bruns, P. K., Muldoon, L. L., Fortin, D., & Neuwelt, E. A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9038-4 · Cited by 77
Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
Butowski, N. A., Chang, S. M., Lamborn, K. R., Polley, M.-Y., Pieper, R. O., Costello, J., VandenBerg, S. R., Parvataneni, R., Nicole, A., Sneed, P. K., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor130 · Cited by 77
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813
Chang, S. M., Zhang, J., Cairncross, J. G., Gilbert, M. R., Bahary, J.-P., Dolinskas, C. A., Chakravarti, A., Aldape, K., Bell, E. H., Schiff, D., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now236 · Cited by 78
Self-citation
Pseudoprogression: Relevance With Respect to Treatment of High-Grade Gliomas
Fink, J. R., Born, D. E., & Chamberlain, M. C. (2011) · Current Treatment Options in Oncology · doi:10.1007/s11864-011-0157-1 · Cited by 76
Prognostic factors for survival in adult patients with recurrent glioblastoma: a decision-tree-based model
de Neurochirurgie, F. T. C. D. N.-O. O. T. S. F., Audureau, É., Chivet, A., Ursu, R., Corns, R. A., Métellus, P., Noël, G., Zouaoui, S., Guyotat, J., Reste, P. L., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2685-4 · Cited by 76
Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis
Khan, M. B., Zhao, Z., Arooj, S., & Liao, G. (2021) · BMC Cancer · doi:10.1186/s12885-021-07889-3 · Cited by 76
Biopsy versus resection for the management of low-grade gliomas
Jiang, B., Chaichana, K. L., Veeravagu, A., Chang, S. D., Black, K. L., & Patil, C. G. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009319.pub3 · Cited by 76
A practical scoring system to determine whether to proceed with surgical resection in recurrent glioblastoma
Park, C., Kim, J. H., Nam, D., Kim, C., Chung, S.-B., Kim, Y.-H., Seol, H. J., Kim, T. M., Choi, S. H., Lee, S., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not069 · Cited by 83
Pros and cons of current brain tumor imaging
Ellingson, B. M., Wen, P. Y., van den Bent, M. J., & Cloughesy, T. F. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou224 · Cited by 76
CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans
Haining, W. N., DAVIES, J. K., Kanzler, H., Drury, L., Brenn, T., Evans, J., Angelosanto, J., Rivoli, S., Russell, K. E. R., George, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0526 · Cited by 76
Diagnosis and treatment in neuro-oncology: an oncological perspective
Rees, J. H. (2011) · British Journal of Radiology · doi:10.1259/bjr/18061999 · Cited by 81
Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients
Silvani, A., Eoli, M., Salmaggi, A., Lamperti, E., Maccagnano, E., Broggi, G., & Boiardi, A. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000013479.64348.69 · Cited by 76
The Usefulness of Dynamic O-(2-18F-Fluoroethyl)-l-Tyrosine PET in the Clinical Evaluation of Brain Tumors in Children and Adolescents
Dunkl, V., Cleff, C., Stoffels, G., Judov, N., Sarikaya-Seiwert, S., Law, I. G., Bøgeskov, L., Nysom, K., Andersen, S. B., Steiger, H.-J., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.148734 · Cited by 75
Intravoxel water diffusion heterogeneity imaging of human high‐grade gliomas
Kwee, T. C., Galbán, C. J., Tsien, C. I., Junck, L., Sundgren, P. C., Ivancevic, M. K., Johnson, T. D., Meyer, C. R., Rehemtulla, A., Ross, B. D., et al. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1441 · Cited by 75
Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series
Chamberlain, M. C., & Johnston, S. K. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0541-5 · Cited by 75
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab
Huang, R. Y., Rahman, R. M., Ballman, K. V., Felten, S. J., Anderson, S. K., Ellingson, B. M., Nayak, L., Lee, E. Q., Abrey, L. E., Galanis, E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3040 · Cited by 75
Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab
Ellingson, B. M., Cloughesy, T. F., Lai, A., Mischel, P. S., Nghiemphu, P. L., Lalezari, S., Schmainda, K. M., & Pope, W. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor079 · Cited by 75
Outcome of Newly Diagnosed Glioblastoma Patients Treated by Radiotherapy plus Concomitant and Adjuvant Temozolomide: A Long-Term Analysis
Erpolat, Ö. P., Akmansu, M., Göksel, F., Bora, H., Yaman, E., & Buyukberber, S. (2009) · Tumori Journal · doi:10.1177/030089160909500210 · Cited by 74
Fractionated Stereotactic Radiotherapy using CyberKnife for the Treatment of Large Brain Metastases: A Dose Escalation Study
Murai, T., Ogino, H., Manabe, Y., Iwabuchi, M., Okumura, T., Matsushita, Y., Tsuji, Y., Suzuki, H., & Shibamoto, Y. (2013) · Clinical Oncology · doi:10.1016/j.clon.2013.11.027 · Cited by 74
Stereotactic Brachytherapy With Iodine-125 Seeds for the Treatment of Inoperable Low-Grade Gliomas in Children: Long-Term Outcome
Ruge, M. I., Simon, T., Suchorska, B., Lehrke, R., Hamisch, C., Koerber, F., Maarouf, M., Treuer, H., Berthold, F., Sturm, V., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3381 · Cited by 74
Phase II study of topotecan in patients with recurrent malignant glioma
Macdonald, D., Cairncross, G., Stewart, D. J., Forsyth, P. A., Sawka, C., Wainman, N., & Eisenhauer, E. A. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010550 · Cited by 74
Self-citation
Salvage chemotherapy for oligodendroglioma
Peterson, K., Paleologos, N. A., Forsyth, P. D., Macdonald, D. R., Cairncross, J. G., & _, _. (1996) · Journal of neurosurgery · doi:10.3171/jns.1996.85.4.0597 · Cited by 74
Self-citation
Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
Prados, M., Cloughesy, T. F., Samant, M. K., Fang, L., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq151 · Cited by 73
Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse
Arevalo, O., Soto, C., Rabiei, P., Kamali, A., Ballester, L. Y., Esquenazi, Y., Zhu, J., & Riascos, R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00460 · Cited by 74
Phase 2 trial of high‐dose rituximab with high‐dose cytarabine mobilization therapy and high‐dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non‐Hodgkin lymphoma
Chen, Y., Batchelor, T. T., Li, S., Hochberg, E. P., Brezina, M., Jones, S. S., Rio, C. D., Curtis, M., Ballen, K. K., Barnes, J. A., et al. (2014) · Cancer · doi:10.1002/cncr.29023 · Cited by 73
Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.
Bartolomei, M., Mazzetta, C., Handkiewicz-Junak, D., Bodei, L., Rocca, P. A., Grana, C. M., Maira, G., Sturiale, C. L., Villa, G., & Paganelli, G. (2004) · PubMed · Cited by 73
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma
Peñas-Prado, M., Hess, K. R., Fisch, M. J., Lagrone, L. W., Groves, M. D., Levin, V. A., de Groot, J., Puduvalli, V. K., Colman, H., Volas-Redd, G. H., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou155 · Cited by 75
The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma
Poulsen, S. H., Urup, T. H., Grunnet, K., Christensen, I. J., Larsen, V. A., Lundemann, M. J., af Rosenschöld, P. M., Poulsen, H. S., & Law, I. G. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3494-2 · Cited by 73
Bevacizumab and glioblastoma: Scientific review, newly reported updates, and ongoing controversies
Field, K. M., Jordan, J. T., Wen, P. Y., Rosenthal, M. A., & Reardon, D. A. (2014) · Cancer · doi:10.1002/cncr.28935 · Cited by 75
Status Quo—Standard-of-Care Medical and Radiation Therapy for Glioblastoma
Becker, K. P., & Yu, J. B. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318244d7eb · Cited by 72
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
Taillibert, S., Vincent, L. A., Granger, B., Marie, Y., Carpentier, C., Guillevin, R., Bellanger, A., Mokhtari, K., Rousseau, A., Psimaras, D., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a413be · Cited by 72
Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma
Yamasaki, F., Kurisu, K., Kajiwara, Y., Watanabe, Y., Takayasu, T., Akiyama, Y., Saito, T., Hanaya, R., & Sugiyama, K. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor038 · Cited by 72
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial
Kesari, S., Ram, Z., & on behalf of EF-14 Trial Investigators (2017) · CNS Oncology · doi:10.2217/cns-2016-0049 · Cited by 73
Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience
Cao, J. Q., Fisher, B. J., Bauman, G. S., Megyesi, J. F., Watling, C., & Macdonald, D. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0766-3 · Cited by 71
Self-citation
Bevacizumab for recurrent alkylator‐refractory anaplastic oligodendroglioma
Chamberlain, M. C., & Johnston, S. K. (2009) · Cancer · doi:10.1002/cncr.24179 · Cited by 71
Differential Gene Expression in Glioblastoma Defined by ADC Histogram Analysis: Relationship to Extracellular Matrix Molecules and Survival
Pope, W. B., Mirsadraei, L., Lai, A., Eskin, A., Qiao, J. X., Kim, H. J., Ellingson, B. M., Nghiemphu, P. L., Kharbanda, S., Soriano, R. H., et al. (2012) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2917 · Cited by 72
Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?
Romagna, A., Unterrainer, M., Schmid‐Tannwald, C., Brendel, M., Tonn, J., Nachbichler, S. B., Muacevic, A., Bartenstein, P., Kreth, F.-W., & Albert, N. L. (2016) · Radiation Oncology · doi:10.1186/s13014-016-0713-8 · Cited by 71
Brain Edema in Neurooncology: Radiological Assessment and Management
Wick, W., & Küker, W. (2004) · Oncology Research and Treatment · doi:10.1159/000077976 · Cited by 71
Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions
Patel, M. D., Vogelbaum, M. A., Barnett, G. H., Jalali, R., & Ahluwalia, M. S. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.703177 · Cited by 74
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma
Reardon, D. A., Vredenburgh, J. J., Sykes, A. D., Desjardins, A., Peters, K. B., Gururangan, S., Sathornsumetee, S., Rich, J. N., Herndon, J. E., & Friedman, H. S. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0631-4 · Cited by 70
A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
Addeo, R., Caraglia, M., Santi, M. S. D., Montella, L., Abbruzzese, A., Parlato, C., Vincenzi, B., Carraturo, M., Faiola, V., Genovese, M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0329-z · Cited by 70
Temozolomide for recurrent low‐grade spinal cord gliomas in adults
Chamberlain, M. C. (2008) · Cancer · doi:10.1002/cncr.23677 · Cited by 70
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951
Gorlia, T., Delattre, J., Brandes, A. A., Kros, J. M., TAPHOORN, M. J. B., Kouwenhoven, M. C. M., Bernsen, H. J. J. A., Frénay, M., Tijssen, C. C., Lacombe, D. A., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.039 · Cited by 70
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma
Kong, D., Lee, J.-I., Kim, W. K., Son, M. J., Lim, D. H., Kim, S. H., Park, K., Kim, J. W., Eoh, W., & Nam, D. (2006) · Oncology Reports · doi:10.3892/or.16.5.1117 · Cited by 70
Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role
Puppa, A. D., Ballin, A., Campello, E., Radu, C., Saggiorato, G., D’Avella, D., Scienza, R., Cella, G., Simioni, P., & Sartori, M. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-12-0957 · Cited by 70
Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study
Wagner, L. M., Perentesis, J. P., Reid, J. M., Ames, M. M., Safgren, S. L., Nelson, M. D., Ingle, A. M., Blaney, S. M., & Adamson, P. C. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22407 · Cited by 70
Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: Phase II study
Giorgio, C. G., Giuffrida, D., Pappalardo, A., Russo, A. D., Santini, D., Salice, P., Blanco, G., Castorina, S., Failla, G., & Bordonaro, R. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.05.026 · Cited by 70
Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma
Prah, M. A., Stufflebeam, S. M., Paulson, E. S., Kalpathy–Cramer, J., Gerstner, E. R., Batchelor, T. T., Barboriak, D. P., Rosen, B. R., & Schmainda, K. M. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4374 · Cited by 70
Salvage Chemotherapy With Tamoxifen for Recurrent Anaplastic Astrocytomas
Chamberlain, M. C., & Kormanik, P. A. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.703 · Cited by 70
Retrospective Comparison of Chemoradiotherapy Followed by Adjuvant Chemotherapy, With or Without Prior Gliadel Implantation (Carmustine) After Initial Surgery in Patients With Newly Diagnosed High-Grade Gliomas
Noël, G., Schött, R., Froelich, S. C., Gaub, M., Boyer, P., Fischer-Lokou, D., Dufour, P., Kehrli, P., & Maitrot, D. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.11.073 · Cited by 69
NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma
Gilbert, M. R., Pugh, S. L., Aldape, K. D., Sorensen, A. G., Mikkelsen, T., Peñas-Prado, M., Bokstein, F., Kwok, Y., Lee, R. J., & Mehta, M. P. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2288-5 · Cited by 69
Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma
Voloschin, A. D., Betensky, R. A., Wen, P. Y., Hochberg, F. H., & Batchelor, T. T. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9464-6 · Cited by 69
Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab
Ellingson, B. M., Cloughesy, T. F., Lai, A., Nghiemphu, P. L., Lalezari, S., Zaw, T. M., Motevalibashinaeini, K., Mischel, P. S., & Pope, W. B. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0638-x · Cited by 69
Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence
Gómez-Río, M. M., Rodrı́guez-Fernández, A., Ramos-Font, C., López-Ramírez, E., & Elvira, J. M. L. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0661-5 · Cited by 69
Antiangiogenesis Treatment for Glioblastoma Multiforme: Challenges and Opportunities
Wong, E. T., & Brem, S. S. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0039 · Cited by 69
Salvage therapy in patients with glioblastoma
Hau, P., Baumgart, U., Pfeifer, K., Bock, A., Jauch, T., Dietrich, J., Fabel, K. S., Grauer, O. M., Wismeth, C., Klinkhammer‐Schalke, M., et al. (2003) · Cancer · doi:10.1002/cncr.11845 · Cited by 69
Loss of Heterozygosity for Loci on Chromosome Arms 1p and 10q in Oligodendroglial Tumors: Relationship to Outcome and Chemosensitivity
Thiessen, B. A., Maguire, J. A., McNeil, K., Huntsman, D. D., Martin, M. A., & Horsman, D. E. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1025689004046 · Cited by 69
Malignant glioma: Should chemotherapy be overthrown by experimental treatments?
Hösli, P., Sappino, A. P., de Tribolet, N., & Dietrich, P. (1998) · Annals of Oncology · doi:10.1023/a:1008267312782 · Cited by 69
Imaging Glioblastoma Posttreatment
Strauß, S., Meng, A., Ebani, E. J., & Chiang, G. C.-Y. (2019) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2019.07.003 · Cited by 68
Low-Dose Chemotherapy in Combination with COX-2 Inhibitors and PPAR-Gamma Agonists in Recurrent High-Grade Gliomas – A Phase II Study
Hau, P., Kunz‐Schughart, L. A., Bogdahn, U., Baumgart, U., Hirschmann, B., Weimann, E., Mühleisen, H., Ruemmele, P., Steinbrecher, A., & Reichle, A. (2007) · Oncology · doi:10.1159/000120028 · Cited by 68

Authors: Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G.
Affiliations: Western University (CA)
ORCID: Cairncross, J G
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 1990-07
Volume: 8
Issue: 7
Pages: 1277-1280
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.1990.8.7.1277
OpenAlex: W1959628099
Cited by: 2,409
References: 11
Citations by year: 2026: 31 · 2025: 21 · 2024: 36 · 2023: 52 · 2022: 53 · 2021: 59 · 2020: 68 · 2019: 75 · 2018: 97 · 2017: 111 · 2016: 125 · 2015: 122 · 2014: 161 · 2013: 186 · 2012: 145
FWCI: 3.90
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: high-grade glioma, supratentorial glioma, response criteria, tumor size measurement, complete response, partial response, stable disease, progressive disease, steroid use, neurologic findings, patient selection, magnetic resonance imaging, computed tomography
MeSH terms: Diagnostic Errors, Drug Evaluation, Glioma, Humans, Magnetic Resonance Imaging, Medical Oncology, Tomography, X-Ray Computed, Supratentorial Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Response criteria for phase II studies of supratentorial malignant glioma.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks